Isoprenoid-independent pathway is involved in apoptosis induced by risedronate,,a bisphosphonate,inwhich Bim plays a critical role in breast cancer cell line MCF-7

Oncology Reports

Volumn 18, Issue 5, 2007, Pages 1291-1298

  Suyama, Keiko ^a   Noguchi, Yoshihiko ^a   Tanaka, Tomoaki ^a   Yoshida, Tomohiko ^a   Shibata, Takahisa ^a   Saito, Yasushi ^a   Tatsuno, Ichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bim; Bisphosphonate; Breast cancer; Isoprenoid

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; BONE DENSITY CONSERVATION AGENT; CALCIUM CHANNEL BLOCKING AGENT; CASPASE; CERIVASTATIN; DRUG DERIVATIVE; ETIDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; ONCOPROTEIN; PYRIDINE DERIVATIVE; RISEDRONIC ACID; SMALL INTERFERING RNA; TERPENE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CALCIUM CHANNEL BLOCKERS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ETIDRONIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; PYRIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TERPENES; TUMOR CELLS, CULTURED;

EID: 38449084047     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hortobagyi GN: Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 29: 134-144, 2002.
2. Mystakidou K, Katsouda E, Stathopoulou E and Vlahos L: Approaches to managing bone metastases from breast cancer: The role of bisphosphonates. Cancer Treat Rev 31: 303-311, 2005. (Pubitemid 41001677)
3. Diel IJ and Mundy GR: Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer 82: 1381-1386, 2000. (Pubitemid 30175901)
4. Diel IJ, Solomayer EF and Bastert G: Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88: 3080-3088, 2000. (Pubitemid 30413194)
5. Lipton A: Toward new horizons: the future of bisphosphonate therapy. Oncologist 9: 38-47, 2004.
6. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J and Pylkkanen L: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224, 2002. (Pubitemid 34831518)
7. Saarto T, Vehmanen L, Virkkunen P and Blomqvist C: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43: 650-656, 2004. (Pubitemid 39563937)
8. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE and Holen I: Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113: 364-371, 2005. (Pubitemid 40038702)
9. Benford HL, McGowan NW, Helfrich MH, Nuttall ME and Rogers MJ: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28: 465-473, 2001. (Pubitemid 32409997)
10. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL and Bataille R: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14: 2048-2056, 1999. (Pubitemid 30026954)
11. Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001. (Pubitemid 32448513)
12. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000. (Pubitemid 30175914)
13. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE and Perrone MH: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33: 1657-1663, 1992.
14. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A and Rogers MJ: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15: 1467-1476, 2000. (Pubitemid 30484516)
15. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J and Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961-2978, 2000. (Pubitemid 30413179)
16. Cafforio P, Dammacco F, Gernone A and Silvestris F: Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891, 2005. (Pubitemid 41214316)
17. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA and Bitterman P: Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157: 1616-1622, 1998.
18. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L and Law RE: Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 205: 1681-1687, 1994.
19. Vitale M, Di Matola T, Rossi G, Laezza C, Fenzi G and Bifulco M: Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology 140: 698-704, 1999. (Pubitemid 29058203)
20. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519, 2002. (Pubitemid 34460459)
21. van de Donk NW, Kamphuis MM, Lokhorst HM and Bloem AC: The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16: 1362-1371, 2002.
22. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, Kohn LD and Saito Y: Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272: 13-16, 1997. (Pubitemid 27021114)
23. Keyomarsi K, Sandoval L, Band V and Pardee AB: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609, 1991.
24. Kim JS, Pirnia F, Choi YH, Nguyen PM, Knepper B, Tsokos M, Schulte TW, Birrer MJ, Blagosklonny MV, Schaefer O, Mushinski JF and Trepel JB: Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 19: 6082-6090, 2000. (Pubitemid 32039383)
25. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J and Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148, 2001. (Pubitemid 32737327)
26. Otsuka Y, Tanaka T, Uchida D, Noguchi Y, Saeki N, Saito Y and Tatsuno I: Roles of cyclin-dependent kinase 4 and p53 in neuronal cell death induced by doxorubicin on cerebellar granule neurons in mouse. Neurosci Lett 365: 180-185, 2004. (Pubitemid 38891778)
27. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC and Lam EW: FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805, 2003.
28. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM and Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000. (Pubitemid 30395820)
29. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001. (Pubitemid 32685845)
30. Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98: 665-672, 1997. (Pubitemid 27386550)
31. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002. (Pubitemid 34920226)
32. Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T and Saijo N: Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 6: 33-37, 1999.
33. Erl W: Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Curr Drug Targets Cardiovasc Haematol Disord 5: 135-144, 2005.
34. Graaf MR, Richel DJ, van Noorden CJ and Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641, 2004. (Pubitemid 39451828)
35. Tatsuno I, Hirai A and Saito Y: Cell-anchorage, cell cytoskeleton, and Rho-GTPase family in regulation of cell cycle progression. Prog Cell Cycle Res 4: 19-25, 2000.
36. Tanaka T, Tatsuno I, Uchida D, Moroo I, Morio H, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Saito Y and Hirai A: Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci 20: 2852-2859, 2000. (Pubitemid 30220310)
37. Tanaka T, Tatsuno I, Noguchi Y, Uchida D, Oeda T, Narumiya S, Yasuda T, Higashi H, Kitagawa M, Nakayama K, Saito Y and Hirai A: Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes. Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression. J Biol Chem 273: 26772-26778, 1998. (Pubitemid 28471694)
38. Terano T, Shiina T, Noguchi Y, Tanaka T, Tatsuno I, Saito Y, Yasuda T, Kitagawa M and Hirai A: Geranylgeranyl-pyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells. J Atherosclerosis Thromb 5: 1-6, 1998.
39. Nishimura M, Tanaka T, Yasuda T, Kurakata S, Kitagawa M, Yamada K, Saito Y and Hirai A: Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate. Kidney Int 55: 520-528, 1999. (Pubitemid 29082878)
40. Tatsuno I, Tanaka T, Oeda T, Yasuda T, Kitagawa M, Saito Y and Hirai A: Geranylgeranylpyrophosphate, a metabolite of mevalonate, regulates the cell cycle progression and DNA synthesis in human lymphocytes. Biochem Biophys Res Commun 241: 376-382, 1997. (Pubitemid 28020109)
41. Li R, Moudgil T, Ross HJ and Hu HM: Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 12: 292-303, 2005. (Pubitemid 40360952)
42. Strasser A, Puthalakath H, Bouillet P, Huang DC, O'Connor L, O'Reilly LA, Cullen L, Cory S and Adams JM: The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. Ann NY Acad Sci 917: 541-548, 2000.